US 10,246,508 B2Granted

Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines

AssigneeChemomab Ltd.

InventorAdi Mor

Life of this patent

Estimating the term…

Abstract

Provided are isolated polyspecific antibodies directed to a unique epitope in the chemokine eotaxin 2. The antibodies bind additional CCR3-binding chemokines. Further provided are methods for using of the antibodies for attenuating the migration of various cells and for treating fibrotic diseases, autoimmune inflammatory disorders, monocyte related disorders or allergic atopic disorders.

Claims3

Dependent claims

A nucleic acid molecule encoding a humanized antibody that binds to at least two CCR3-binding chemokines wherein said nucleic acid molecule comprises the sequence denoted by SEQ ID NO:

1 and SEQ ID NO:
2.

Dependencies are inferred from the claim text.

Facts

Application: 15/122,241Filed 4 Mar 2015 · us provisional application
Priority: 4 Mar 2014
Published: US 2016/0368979 A122 Dec 2016
Granted: 2 Apr 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification22 codes

C07K 16/24
Against material from animals or humans: against cytokines, lymphokines or interferons
A61P 1/10
Drugs for disorders of the alimentary tract or the digestive system: laxatives
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics
A61P 9/10
Drugs for disorders of the cardiovascular system: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary…

Family

Application61/947,852Us provisional application · filed 4 Mar 2014
US 2016/0368979 A1Pre-grant publication · published 22 Dec 2016
US 10,246,508 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

patentgrepSearch patents

Back to results